Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)

Hideaki Hanaki; Yoshio Yamaguchi; Chie Yanagisawa; Kazuaki Uehara; Hidehito Matsui; Yukie Yamaguchi; Yasuko Hososaka; Kazunari Barada; Fumiko Sakai; Yasuko Itabashi; Shinsuke Ikeda; Koichiro Atsuda; Haruo Tanaka; Takashi Inamatsu; Ariaki Nagayama; Keisuke Sunakawa

doi:10.1007/s10156-004-0371-x

Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)

Hideaki Hanaki, Yoshio Yamaguchi, Chie Yanagisawa, Kazuaki Uehara, Hidehito Matsui, Yukie Yamaguchi, Yasuko Hososaka, Kazunari Barada, Fumiko Sakai, Yasuko Itabashi, Shinsuke Ikeda, Koichiro Atsuda, Haruo Tanaka, Takashi Inamatsu, Ariaki Nagayama, Keisuke Sunakawa

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

We could not detect hetero-vancomycin-intermediate resistant Staphylococcus aureus (hetero-VISA), according to the definition of hetero-VISA, from the clinical isolates of 140 methicillin-resistant S. aureus (MRSA) strains. However, 15 β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) strains were detected from the same strains. We screened 1882 MRSA clinical isolates obtained in 2002 from 21 institutes throughout Japan. The detection rate of blood-isolated BIVR was 12.6% (19/151), and that of nonblood-isolated BIVR was 4.9% (85/1731; P < 0.001; χ² test). Uridine-diphosphate-N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-lysine, used as the peptidoglycan material of S. aureus, showed the same results as β-lactam antibiotics in BIVR.

Original language	English
Pages (from-to)	104-106
Number of pages	3
Journal	Journal of Infection and Chemotherapy
Volume	11
Issue number	2
DOIs	https://doi.org/10.1007/s10156-004-0371-x
Publication status	Published - 2005 Apr
Externally published	Yes

Keywords

Antagonism
BIVR
Vancomycin
β-Lactam antibiotics

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10156-004-0371-x

Cite this

Hanaki, H., Yamaguchi, Y., Yanagisawa, C., Uehara, K., Matsui, H., Yamaguchi, Y., Hososaka, Y., Barada, K., Sakai, F., Itabashi, Y., Ikeda, S., Atsuda, K., Tanaka, H., Inamatsu, T., Nagayama, A., & Sunakawa, K. (2005). Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). Journal of Infection and Chemotherapy, 11(2), 104-106. https://doi.org/10.1007/s10156-004-0371-x

Hanaki, H, Yamaguchi, Y, Yanagisawa, C, Uehara, K, Matsui, H, Yamaguchi, Y, Hososaka, Y, Barada, K, Sakai, F, Itabashi, Y, Ikeda, S, Atsuda, K, Tanaka, H, Inamatsu, T, Nagayama, A & Sunakawa, K 2005, 'Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)', Journal of Infection and Chemotherapy, vol. 11, no. 2, pp. 104-106. https://doi.org/10.1007/s10156-004-0371-x

@article{6a63b024de4a44ef9db952d31390c3b9,

title = "Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)",

abstract = "We could not detect hetero-vancomycin-intermediate resistant Staphylococcus aureus (hetero-VISA), according to the definition of hetero-VISA, from the clinical isolates of 140 methicillin-resistant S. aureus (MRSA) strains. However, 15 β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) strains were detected from the same strains. We screened 1882 MRSA clinical isolates obtained in 2002 from 21 institutes throughout Japan. The detection rate of blood-isolated BIVR was 12.6% (19/151), and that of nonblood-isolated BIVR was 4.9% (85/1731; P < 0.001; χ2 test). Uridine-diphosphate-N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-lysine, used as the peptidoglycan material of S. aureus, showed the same results as β-lactam antibiotics in BIVR.",

keywords = "Antagonism, BIVR, Vancomycin, β-Lactam antibiotics",

author = "Hideaki Hanaki and Yoshio Yamaguchi and Chie Yanagisawa and Kazuaki Uehara and Hidehito Matsui and Yukie Yamaguchi and Yasuko Hososaka and Kazunari Barada and Fumiko Sakai and Yasuko Itabashi and Shinsuke Ikeda and Koichiro Atsuda and Haruo Tanaka and Takashi Inamatsu and Ariaki Nagayama and Keisuke Sunakawa",

year = "2005",

month = apr,

doi = "10.1007/s10156-004-0371-x",

language = "English",

volume = "11",

pages = "104--106",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)

AU - Hanaki, Hideaki

AU - Yamaguchi, Yoshio

AU - Yanagisawa, Chie

AU - Uehara, Kazuaki

AU - Matsui, Hidehito

AU - Yamaguchi, Yukie

AU - Hososaka, Yasuko

AU - Barada, Kazunari

AU - Sakai, Fumiko

AU - Itabashi, Yasuko

AU - Ikeda, Shinsuke

AU - Atsuda, Koichiro

AU - Tanaka, Haruo

AU - Inamatsu, Takashi

AU - Nagayama, Ariaki

AU - Sunakawa, Keisuke

PY - 2005/4

Y1 - 2005/4

N2 - We could not detect hetero-vancomycin-intermediate resistant Staphylococcus aureus (hetero-VISA), according to the definition of hetero-VISA, from the clinical isolates of 140 methicillin-resistant S. aureus (MRSA) strains. However, 15 β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) strains were detected from the same strains. We screened 1882 MRSA clinical isolates obtained in 2002 from 21 institutes throughout Japan. The detection rate of blood-isolated BIVR was 12.6% (19/151), and that of nonblood-isolated BIVR was 4.9% (85/1731; P < 0.001; χ2 test). Uridine-diphosphate-N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-lysine, used as the peptidoglycan material of S. aureus, showed the same results as β-lactam antibiotics in BIVR.

AB - We could not detect hetero-vancomycin-intermediate resistant Staphylococcus aureus (hetero-VISA), according to the definition of hetero-VISA, from the clinical isolates of 140 methicillin-resistant S. aureus (MRSA) strains. However, 15 β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) strains were detected from the same strains. We screened 1882 MRSA clinical isolates obtained in 2002 from 21 institutes throughout Japan. The detection rate of blood-isolated BIVR was 12.6% (19/151), and that of nonblood-isolated BIVR was 4.9% (85/1731; P < 0.001; χ2 test). Uridine-diphosphate-N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-lysine, used as the peptidoglycan material of S. aureus, showed the same results as β-lactam antibiotics in BIVR.

KW - Antagonism

KW - BIVR

KW - Vancomycin

KW - β-Lactam antibiotics

UR - http://www.scopus.com/inward/record.url?scp=20844455771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844455771&partnerID=8YFLogxK

U2 - 10.1007/s10156-004-0371-x

DO - 10.1007/s10156-004-0371-x

M3 - Article

C2 - 15856381

AN - SCOPUS:20844455771

SN - 1341-321X

VL - 11

SP - 104

EP - 106

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 2

ER -

Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this